Alexander C Huang, MD

Selected Publications

• Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan P, Kier M, Laughlin AI, Kothari S, Giles JR, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney D, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn A, Blank C, Weber J, Mitchell TC, Farwell MD, Herati R, Huang AC. : Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells. Cancer Cell 42(9) : 1582-1597, Sept 2024
• Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Matthew D, Chen Q, Khan O, Wu JE, ALcade V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali, DAA, Wherry EJ. : LAB-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK expression and cytotoxicity. Cell 187(16) : 4336-4354, August 2024
• Mathew D, Maramareis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ, Minn AJ. : Combined JAK Inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384(6702) June 2024
• Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD. : FDG PET/CT Imaging 1 Week after a Singel Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma Clin Cancer Res 30(9) May 2024
• Beltra JC, Abdel-Hakeem MS, Manne S, Zhang Z, Huang H, Kurachi M, Su L, Picton L, Ngiow SF, Muroyama Y, Casella V, Huang YJ, Giles JR, Mathew D, Belman J, Klapholz M, Decaluwe H, Huang AC, Berger SL, Garcia KC, Wherry EJ. : Stat5 opposes the transcription factor Tox and rewires exhausted CD3(+) T cells toward durable effector-like states during chronic antigen exposure. Immunity 56(12) : 2699-2718, December 2023
• Kevin L Ma, Cimarron E Sharon, Andrew Kossenkov, Lynn M Schuchter, Ravi K Amaravadi, Tara C Mitchell, John T Miura, Xiaowei Xu, Alexander C Huang, Giorgos C Karakousis : Immune microenvironment in sentinel lymph nodes of high-risk clinical stage IIB/C melanoma Society for Melanoma Research (SMR) Congress, Philadelphia, PA. November 2023 Notes: "Poster Presentation"
• Guanning Wang1, Daniel Yoon2, Justin Kim1, Aaron Nickie1, Stella Park1, Ajeya Nandi1, Patrick Yan1, Mary Carberry1, Lydia Giles1, Khushboo Patel1, Ravi K. Amaravadi1, Lynn M. Schuchter1, Giorgos C. Karakousis1, Xiaowei Xu1, Tara. C. Mitchell, Alexander C. Huang : Antigen-specific profiling for neoadjuvant anti-PD-1 therapy in melanoma Society for Melanoma Research (SMR Congress), Philadelphia, PA. November 2023 Notes: "Poster Presentation"
• Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, Apostolidis SA, Mathew D, Fulmer B, Williams JC, McKeague ML, Pattekar A, Goode A, Nasta S, Baxter AE, Giles JR, Skelly AN, Felley LE, McLaughlin M, Weaver J, Kuthuru O, Dougherty J, Adamski S, Long S, Kee M, Clendenin C, da Silva Antunes R, Grifoni A, Weiskopf D, Sette A, Huang AC, Rader DJ, Hensley SE, Bates P, Greenplate AR, Wherry EJ. : Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV2 breakthrough infection. Nat Immunol 24(10) : 1711-1724, Oct 2023
• Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. : Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Ann Oncol 34 (9) : 806-812, Sep 2023
• Sharon CE, Tortorello GN, MA KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Muira JT, Karakousis GC, Mitchell TC : Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneus melanoma. Ann Oncol 34(9) : 806-812, September 2023